Skip to main content

Table 3 Baseline characteristics of clinical trials in primary and secondary endpoints

From: Clinical outcomes meta-analysis: measuring subendocardial perfusion and efficacy of transmyocardial laser revascularization with nuclear imaging

  Control (%) Treatment (%) p value no. studies
Demographics
 Female 29.5 29.6 0.92 14
 Mean age 62.1 61.8 0.32 13
Medical History
 CABG 66.7 66.9 0.37 14
 PTCA 31.5 29.4 0.49 12
 Acute MI 62.7 62.8 0.95 15
 CHF 21.6 20.5 0.74 7
Cardiac Status
 Mean LVEF 49.4 49.5 0.95 11
 NYHA Class III 55.6 52.6 0.19 8
 NYHA Class IV 44.4 47.4 0.19 8
 Unstable angina 9.0 24.2 <0.01 5
Risk Factors
 HTN 64.5 62.9 0.55 9
 Hypercholesterolemia/HLD 80.6 73.2 0.01 5
 DM 36.8 35.7 0.65 13
 Tobacco use 31.4 30.6 0.56 11
  1. control = MM and CABG treatment = TMR and CABG/TMR